A food allergy refers to an adverse reaction of the body’s immune system to certain foods which are perceived to be a danger to the body. While most allergic reactions are mild and easily managed, these responses can also be serious and life-threatening, causing anaphylaxis and even death.
It is estimated that up to 6 percent of children under the age of five have a food allergy, whereas food allergies only affect 3-4 percent of adults. However, the prevalence of food allergies is on the rise and is thought to account for around 150-200 deaths per year.
Allergy Therapeutics (LON:AGY) is an international commercial biotechnology group focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.